888集团电子游戏(官方VIP认证)-Green Game Store

Introduction

The continuous development of high-throughput sequencing (NGS) technology and the significant reduction in sequencing costs have provided favorable conditions for the realization of precise and accurate treatment of tumor patients in clinical practice.Annoroad has earnestly selected 868 genes that are closely related to tumors, covering all the genes recommended by the guidelines and clinical hotspot genes, and analyzes the relationship between 288 targeted drugs/immunization drug and gene variants, helps with gene detection in lung cancer patients, especially for those with recurrence and metastasis at advanced stage.

According to different samples available from patients, Annoroad has developed two types of testing products:

AnnoUltra-ctDNA test:It is applicable for blood samples. After blood collection, NGS technology is used to carry out ctDNA test.

AnnoPro-tissue test:It is applicable for fresh tissue samples (including fresh pleural effusion samples), puncture tissue, paraffin section tissue, etc., NGS technology is used for gene detection.

Authoritative basis

Product design covers test items in NCCN, ESMO, WHO, CSCO authoritative guidelines；
Covers high-impact-factor academic achievements and major discovered genes at ASCO conferences
Covers all genes detected by FoundationOne CDx and MSK-IMPACT.

Meet medical needs

Immunotherapy medication reference, targeted therapy medication reference, chemotherapy efficacy and toxic and side effects prediction, and in-depth exploration of molecular mechanism.

Immunotherapy multidimensional detection

The drug list shows the approval status of the drugs and is only for reading by medical and pharmacy professionals. Please purchase or use specific drugs under the guidance of a pharmacist, and please follow the drug instructions at the same time.

AnnoPro 868 core composition

Advantages

Comprehensive test items
It can detect 868 tumor medication-related genes at one time, and interpret the relationship between 288 targeted drugs/immunization drugs and gene mutations
Sensitive and Accurate
It can detect low-frequency mutations as low as 0.1% with an accuracy up to 99.9% or higher
Precise Interpretation
It adopts multiple international authoritative databases and professional medical genetic interpretation team
Unique advantages of ctDNA testing
Non-invasive and convenient, only 10 ml of blood is required; Overcome the omission of detection information caused by tumor heterogeneity; Realize dynamic monitoring
Flexible detection of various samples
Tissue samples and blood samples can be detected on the same Panel
Different samples can be compared and analyzed to determine tumor heterogeneity
Minimally invasive blood test enables dynamic monitoring and early detection of drug resistance related mutations
No separate sampling for detection was required as the hydrothorax and ascite were close to the lesion.

Process

Applicable

Tumor patients with drug resistance during treatment or poor treatment effect;
Tumor patients who are candidates for multi-gene and multi-site detection to formulate a comprehensive treatment regimen;
Tumor patients who cannot obtain surgical or punctured tissue (applicable for ctDNA test);
Tumor patients with existing tissue slices stored for more than 1 year (applicable for ctDNA test).